Type 2 diabetes and risk of cognitive impairment and dementia

Current Neurology and Neuroscience Reports

Volumn 7, Issue 5, 2007, Pages 373-380

  Whitmer, Rachel A ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; CYTOKINE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; ORAL ANTIDIABETIC AGENT; STREPTOZOCIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN CIRCULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GENETIC RISK; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PATHOGENESIS; REGULATORY MECHANISM; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; VASCULAR DISEASE;

AMYLOID BETA-PROTEIN; BRAIN; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; DEMENTIA; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN; RISK FACTORS;

EID: 34548711907     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-007-0058-7     Document Type: Review

References (110)

1. World Health Organization: Report of the Expert Committee on Diabetes. Geneva, Switzerland; 1980. Report No.: 646.
2. Resnick HE, Harris MI, Brock DB, Harris TB: American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2000, 23:176-180.
3. Narayan KM, Gregg EW, Fagot-Campagna A, et al.: Diabetes: a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract 2000, 50(Suppl 2):77-84.
4. Zimmet P: The burden of type 2 diabetes: Are we doing enough? Diabetes Metab 2003, 29:6S9-18.
5. Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998, 21:518-524.
6. Hebert LE, Beckett LA, Scherr PA, Evans DA: Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 2001, 15:169-173.
7. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB: Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 2000, 24:855-872.
8. Zhao W, Chen H, Xu H, et al.: Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 1999, 74:34893-34902.
9. Gispen WH, Biessels GJ: Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000, 23:542-549.
10. Zhao WQ, Alkon DL: Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 2001, 177:125-134.
11. Zhao WQ, Chen H, Quon MJ, Alkon DL: Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004, 490:71-81.
12. Frolich L, Blum-Degen D, Bernstein HG, et al.: Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998, 105:423-438.
13. Hoyer S: Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 1998, 105:415-422.
14. Edland SD: Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease. J Mol Neurosci 2004, 23:213-217.
15. Farris W, Mansourian S, Chang Y, et al.: Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003, 100:4162-4167.
16. Farris W, Leissring MA, Hemming ML, et al.: Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry 2005, 44:6513-6525.
17. Blomqvist ME, Chalmers K, Andreasen N, et al.: Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. Neurobiol Aging 2005, 26:795-802.
18. Vanhanen M, Soininen H: Glucose intolerance, cognitive impairment and Alzheimer's disease. Curr Opin Neurol 1998, 11:673-677.
19. Watson GS, Peskind ER, Asthana S, et al.: Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003, 60:1899-1903.
20. Watson GS, Craft S: The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003, 17:27-45.
21. Craft S, Peskind E, Schwartz MW, et al.: Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998, 50:164-168.
22. Craft S, Watson GS: Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004, 3:169-178.
23. Ott A, Stolk RP, Hofman A, et al.: Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996, 39:1392-1397.
24. Ott A, Stolk RP, van Harskamp F, et al.: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937-1942.
25. Munch G, Schinzel R, Loske C, et al.: Alzheimer's disease: synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 1998, 105:439-461.
26. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995, 46:223-234.
27. Brownlee M: Negative consequences of glycation. Metabolism 2000, 49(2 Suppl 1):9-13.
28. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 2001, 44:129-146.
29. Heimer J, Dickson D: Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 1997, 49:1306-1311.
30. Peila R, Rodriguez BL, Launer LJ: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002, 51:1256-1562.
31. Schmidt R, Launer LJ, Nilsson LG, et al.: Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 2004, 53:687-692.
32. Biessels GJ, Kappelle AC, Bravenboer B, et al.: Cerebral function in diabetes mellitus. Diabetologia 1994, 37:643-650.
33. Kamal A, Biessels GJ, Urban IJ, Gispen WH: Hippocampal synaptic plasticity in streptozotocin-diabetic rats: impairment of long-term potentiation and facilitation of long-term depression. Neuroscience 1999, 90:737-745.
34. Magarinos AM, McEwen BS: Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc Natl Acad Sci U S A 2000, 97:11056-11061.
35. Li ZG, Zhang W, Grunberger G, Sima AA: Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res 2002, 946:221-231.
36. Whitmer RA, Sidney S, Selby J, et al.: Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005, 64:277-281.
37. Bruce DG, Harrington N, Davis WA, Davis TM: Dementia and its associations in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2001, 53:165-172.
38. Curb JD, Rodriguez BL, Abbott RD, et al.: Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999, 52:971-975.
39. Leibson CL, Rocca WA, Hanson VA, et al.: The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 1997, 826:422-427.
40. Luchsinger JA, Tang MX, Stern Y, et al.: Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemio1 2001, 154:635-641.
41. Macknight C, Rockwood K, Await E, McDowell I: Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002, 14:77-83.
42. Curb JD, Rodriguez BL, Abbott RD, et al.: Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999, 52:971-975.
43. Hassing LB, Johansson B, Nilsson SE, et al.: Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr 2002, 14:239-248.
44. Ott A, Stolk RP, Hofman A, et al.: Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996, 39:1392-1397.
45. Brayne C, Gill C, Huppert FA, et al.: Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 1998, 9:175-180.
46. Haan MN, Shemanski L, Jagust WJ, et al.: The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999, 282:40-46.
47. Xu WL, Qiu CX, Wahlin A, et al.: Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004, 63:1181-1186.
48. Nielson KA, Nolan JH, Berchtold NC, et al.: Apolipoprotein-E genotyping of diabetic dementia patients: Is diabetes rare in Alzheimer's disease? J Am Geriatr Soc 1996, 44:897-904.
49. Moroney JT, Tang MX, Berglund L, et al.: Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999, 282:254-260.
50. Yanagisawa K: Cholesterol and pathological processes in Alzheimer's disease. J Neurosci Res 2002, 70:361-366.
51. Hofman A, Ott A, Breteler MM, et al.: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997, 349:151-154.
52. Frishman WH: Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Dis 2002, 4:380-386.
53. in't Veld BA, Ruitenberg A, Hofman A, et al.: Antihypertensire drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001, 22:407-412.
54. Skoog I, Lernfelt B, Landahl S, et al.: 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347:1141-1145.
55. Tzourio C, Anderson C, Chapman N, et al.: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163:1069-1075.
56. Elias PK, Elias MF, D'Agostino RB, et al.: NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 1997, 20:1388-1395.
57. Hacbinski V, Munoz DG: Cerebrovascular pathology in Alzheimer's disease: cause, effect or epiphenomenon? Ann N Y Acad Sci 1997, 826:1-6.
58. Breteler MM, Claus JJ, van Duijn CM, et al.: Epidemiology of Alzheimer's disease. Epidemiol Rev 1992, 14:59-82.
59. de la Torre JC, Mussivand T: Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 1993, 15:146-153.
60. Wong TY, Klein R, Sharrett AR, et al.: Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study. Stroke 2002, 33:1487-1492.
61. Merchant C, Tang MX, Albert S, et al.: The influence of smoking on the risk of Alzheimer's disease. Neurology 1999, 52:1408-1412.
62. Tyas SL, White LR, Petrovitch H, et al.: Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2003, 24:589-596.
63. Mooradian AD: Central nervous system complications of diabetes mellitus: a perspective from the blood-brain barrier. Brain Res Brain Res Rev 1997, 23:210-218.
64. Hachinski V, Munoz D: Vascular factors in cognitive impairment: Where are we now? Ann N Y Acad Sci 2000, 903:1-5.
65. Miyakawa T, Uehara Y, Desaki J, et al.: Morphological changes of microvessels in the brain with Alzheimer's disease. Jpn J Psychiatry Neurol 1988, 42:819-824.
66. Kalaria RN: The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992, 4:226-260.
67. Farkas E, Luiten PG: Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001, 64:575-611.
68. Moody DM, Brown WR, Challa VR, et al.: Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer's disease. Ann N Y Acad Sci 1997, 826:103-116.
69. Kalmijn S, Feskens EJ, Launer LJ, et al.: Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995, 38:1096-1102.
70. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D: Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996, 27:2230-2235.
71. Strachan MW, Deary IJ, Ewing FM, Frier BM: Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997, 20:438-445.
72. Stewart R, Liolitsa D: Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999, 16:93-112.
73. Yaffe K GE: Diabetes Mellitus and Cognition. In Harrison's Principles of Internal Medicine. Edited by Braunwald E, Fauci AS, Isselbacher KJ, et al.: New York: McGraw-Hill; 2001.
74. Gregg EW, Yaffe K, Cauley JA, et al.: Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000, 160:174-180.
75. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K: Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 2004, 164:1327-1333.
76. Elias PK, Elias MF, D'Agostino RB, et al.: NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 1997, 20:1388-1395.
77. Wu JH, Haan MN, Liang J, et al.: Impact of diabetes on cognitive function among older Latinos: a population-based cohort study. J Clin Epidemiol 2003, 56:686-693.
78. Hassing LB, Grant MD, Hofer SM, et al.: Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc 2004, 10:599-607.
79. Arvanitakis Z, Wilson RS, Bienias JL, et al.: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004, 61:661-666.
80. Yaffe K, Blackwell T, Kanaya AM, et al.: Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004, 63:658-663.
81. Wu JH, Haan MN, Liang J, et al.: Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemiol 2003, 13:369-376.
82. Logroscino G, Kang JH, Grodstein F: Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ 2004, 328:5480.
83. Gavin JR: New classification and diagnostic criteria for diabetes mellitus. Clin Cornerstone 1998, 1:1-12.
84. Newcomer JW, Craft S, Hershey T, et al.: Glucocorticoid-induced impairment in declarative memory performance in adult humans. J Neurosci 1994, 14:2047-2053.
85. Messier C, Gagnon M, Knott V: Effect of glucose and peripheral glucose regulation on memory in the elderly. Neurobiol Aging 1997, 18:297-304.
86. Messier C, Desrochers A, Gagnon M: Effect of glucose, glucose regulation, and word imagery value on human memory. Behav Neurosci 1999, 113:431-438.
87. Messier C, Gagnon M: Glucose regulation and brain aging. J Nutr Health Aging 2000, 4:208-213.
88. Worrall GJ, Chaulk PC, Moulton N: Cognitive function and glycosylated hemoglobin in older patients with type II diabetes. J Diabetes Complications 1996, 10:320-324.
89. Naor M, Steingruber HJ, Westhoff K, et al.: Cognitive function in elderly non-insulin-dependent diabetic patients before and after inpatient treatment for metabolic control. J Diabetes Complications 1997, 11:40-46.
90. Testa MA, Simonson DC: Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998, 280:1490-1496.
91. Gradman TJ, Laws A, Thompson LW, Reaven GM: Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 1993, 41:1305-1312.
92. Meneilly GS, Cheung E, Tessier D, et al.: The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 1993, 48:117-121.
93. Yaffe K, Whitmer RA, Krueger K, et al.: Glycosylated hemoglobin level and development of cognitive impairment or dementia in older women. J Nutr Health Aging 2006, 4:293-295.
94. Enzinger C, Fazekas F, Matthews PM, et al.: Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 2005, 64:1704-1711.
95. Kalmijn S, Feskens EJ, Launer LJ, et al.: Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995, 38:1096-1102.
96. Kuusisto J, Koivisto K, Mykkanen L, et al.: Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension 1993, 22:771-779.
97. Kern W, Peters A, Fruehwald-Schultes B, et al.: Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001, 74:270-280.
98. Craft S, Asthana S, Newcomer JW, et al.: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 1999, 56:1135-1140.
99. Biessels GJ, Kamal A, Ramakers GM, et al.: Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 1996, 45:1259-1266.
100. Lannert H, Hoyer S: Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998, 112:1199-1208.
101. Biessels GJ, Kamal A, Urban IJ, et al.: Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res 1998, 800:125-135.
102. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137.
103. Barzilay JI, Abraham L, Heckbert SR, et al.: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50:2384-2389.
104. Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
105. Festa A, D'Agostino R Jr, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
106. Schmidt R, Schmidt H, Curb JD, et al.: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002, 52:168-174.
107. Campbell IL, Abraham CR, Masliah E, et al.: Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A 1993, 90:10061-10065.
108. Weaver JD, Huang MH, Albert M, et al.: Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002, 59:371-378.
109. Yaffe K, Lindquist K, Penninx BW, et al.: Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61:76-80.
110. Yaffe K, Kanaya A, Lindquist K, et al.: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292:2237-2242.